Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
1. Avidity's del-zota shows unprecedented improvement in DMD clinical trials. 2. Significant reductions in creatine kinase and increased dystrophin production observed. 3. BLA submission to FDA planned by end of 2025 for accelerated approval. 4. Ongoing trials demonstrate significant disease progression reversal in patients. 5. Del-zota's safety profile remains favorable with mostly mild adverse events.